Abstract
Cardiovascular risk factors, irregardless of their assessment modalities, are based on cardiovascular health. Lifestyle influences metabolic profiles and these changes affect cardiovascular risk factors.
Cardiovascular risk factors can be classified into three basic categories: 1. Predisposing risk factors (e.g., age, gender, medical history, and genetic factors); 2. Clinical and metabolic factors (e.g., hypertension, changes in lipid metabolism, diabetes mellitus, obesity, metabolic syndrome, homocysteine, serum uric acid concetntrations, and L-arginine dimethylated derivatives); 3. Modifying behavioral factors (e.g., cigarette smoking, high caloric diet, alcohol intake, sedentary life). Some of these factors are metabolic components of body metabolism because they act by metabolic reactions while others characterized by structural alterations of the cardiovascular system, at least initially, exert their harmful effects by metabolic substrates.
Metabolic responses such as biochemical substances, drugs or others, that act initially as cardiovascular risk factors, identify that an early treatment of the altered parameters observed should be a useful approach to reduce the rate of heart attacks with a significant improvement in the outcome of cardiovascular disease.
Keywords: Cardiovascular risk factor (s), metabolic response, heart and blood vessel rate.
Current Pharmaceutical Design
Title:Modification of Lifestyle Factors are Needed to Improve the Metabolic Health of Patients with Cardiovascular Disease Risk
Volume: 20 Issue: 39
Author(s): Linda Landini
Affiliation:
Keywords: Cardiovascular risk factor (s), metabolic response, heart and blood vessel rate.
Abstract: Cardiovascular risk factors, irregardless of their assessment modalities, are based on cardiovascular health. Lifestyle influences metabolic profiles and these changes affect cardiovascular risk factors.
Cardiovascular risk factors can be classified into three basic categories: 1. Predisposing risk factors (e.g., age, gender, medical history, and genetic factors); 2. Clinical and metabolic factors (e.g., hypertension, changes in lipid metabolism, diabetes mellitus, obesity, metabolic syndrome, homocysteine, serum uric acid concetntrations, and L-arginine dimethylated derivatives); 3. Modifying behavioral factors (e.g., cigarette smoking, high caloric diet, alcohol intake, sedentary life). Some of these factors are metabolic components of body metabolism because they act by metabolic reactions while others characterized by structural alterations of the cardiovascular system, at least initially, exert their harmful effects by metabolic substrates.
Metabolic responses such as biochemical substances, drugs or others, that act initially as cardiovascular risk factors, identify that an early treatment of the altered parameters observed should be a useful approach to reduce the rate of heart attacks with a significant improvement in the outcome of cardiovascular disease.
Export Options
About this article
Cite this article as:
Landini Linda, Modification of Lifestyle Factors are Needed to Improve the Metabolic Health of Patients with Cardiovascular Disease Risk, Current Pharmaceutical Design 2014; 20 (39) . https://dx.doi.org/10.2174/1381612820666140417094458
DOI https://dx.doi.org/10.2174/1381612820666140417094458 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Kidney and the Sympathetic System: A Short Review
Current Clinical Pharmacology Ectodomain Shedding of ACE and ACE2 as Regulators of Their Protein Functions
Current Enzyme Inhibition Editorial (Thematic Issue: The Life Cycle of the Heart Failure Patient)
Current Cardiology Reviews Sympathetic Overactivity in Hypertension and Cardiovascular Disease
Current Vascular Pharmacology Nontraditional Cardiovascular Risk Factors in Pediatric Type 1 Diabetes
Current Diabetes Reviews Nesfatin/Nucleobindin-2 (NUCB2) and Glucose Homeostasis
Current Hypertension Reviews The Role of Polyunsaturated Fatty Acids (PUFA) in the Treatment of Dyslipidemias
Current Pharmaceutical Design Spontaneous Chest Abscess Caused by Salmonella Enterica subsp. Arizonae in the Desert Southwest; A Case Report and Review of the Current Literature
Infectious Disorders - Drug Targets Structure-based Drugs Design Studies on Spleen Tyrosine Kinase Inhibitors
Letters in Drug Design & Discovery Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications
Current Pharmaceutical Design Potential Mechanisms of Failure in the Sudden Infant Death Syndrome
Current Pediatric Reviews Antithrombotic Treatment after Atrial Fibrillation Ablation
Current Pharmaceutical Design Functional Cardiovascular Effects of Angiotensin Peptides: Focus on Atherosclerosis and Hypertension
Current Hypertension Reviews Retinal Protein O-GlcNAcylation and the Ocular Renin-angiotensin System: Signaling Cross-roads in Diabetic Retinopathy
Current Diabetes Reviews Organoselenium Compounds as Potential Neuroprotective Therapeutic Agents
Current Organic Chemistry Physiological Significance and Therapeutic Potential of Adrenomedullin in Pulmonary Hypertension
Cardiovascular & Hematological Disorders-Drug Targets Perioperative Management of Intracranial Aneurysm and Subarachnoid Hemorrhage
Current Pharmaceutical Design Ages of Onset of Mood and Anxiety Disorders in Fragile X Premutation Carriers
Current Psychiatry Reviews Evaluation of the Risk/Benefit Ratio of Old and New Anti-Inflammatory Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry The Multimodal Treatment of Acromegaly: Current Status and Future Perspectives
Endocrine, Metabolic & Immune Disorders - Drug Targets